Dark therapy

Last updated

Dark therapy is the practice of keeping people in complete darkness for extended periods of time in an attempt to treat psychological conditions. The human body produces the melatonin hormone, which is responsible for supporting the circadian rhythms. Darkness seems to help keep these circadian rhythms stable. [1]

Dark therapy was said to be founded by a German anthropologist by the name of Holger Kalweit. [2] A form of dark therapy is to block blue wavelength lights to stop the disintegration of melatonin. [3]

This dark therapy concept was originated back in 1998 from a research which suggested that systematic exposure to darkness might alter people's mood. [4] Original studies enforced 14 hours of darkness to bipolar patients for three nights straight. This study showed a decrease of manic episodes in the patients. [5] Participation in this study became unrealistic, as patients did not want to participate in treatment of total darkness from 6 p.m. to 8 a.m. [6] More recently, with the discovery of intrinsically photosensitive retinal ganglion cells, it has been hypothesized that similar results could be achieved by blocking blue light, as a potential treatment for bipolar disorder. [7] [8] Moreover, researchers exploring blue-blocking glasses have so far considered dark therapy only as an add-on treatment to be used together with psychotherapy, rather than a replacement for other therapies. [9]

Another study consisting of healthy females and males suggested that a single exposure to blue light after being kept in a dim setting could reduce sleepiness. [10] Contrary to the original claim that decreasing the amount of blue light could help with insomnia, this study suggested improvement with blue light exposure.

See also

Related Research Articles

<span class="mw-page-title-main">Bipolar disorder</span> Mental disorder that causes periods of depression and abnormally elevated mood

Bipolar disorder, previously known as manic depression, is a mental disorder characterized by periods of depression and periods of abnormally elevated mood that each last from days to weeks. If the elevated mood is severe or associated with psychosis, it is called mania; if it is less severe, it is called hypomania. During mania, an individual behaves or feels abnormally energetic, happy or irritable, and they often make impulsive decisions with little regard for the consequences. There is usually also a reduced need for sleep during manic phases. During periods of depression, the individual may experience crying and have a negative outlook on life and poor eye contact with others. The risk of suicide is high; over a period of 20 years, 6% of those with bipolar disorder died by suicide, while 30–40% engaged in self-harm. Other mental health issues, such as anxiety disorders and substance use disorders, are commonly associated with bipolar disorder.

Bipolar I disorder is a type of bipolar spectrum disorder characterized by the occurrence of at least one manic episode, with or without mixed or psychotic features. Most people also, at other times, have one or more depressive episodes.

Mania, also known as manic syndrome, is a mental and behavioral disorder defined as a state of abnormally elevated arousal, affect, and energy level, or "a state of heightened overall activation with enhanced affective expression together with lability of affect." During a manic episode, an individual will experience rapidly changing emotions and moods, highly influenced by surrounding stimuli. Although mania is often conceived as a "mirror image" to depression, the heightened mood can be either euphoric or dysphoric. As the mania intensifies, irritability can be more pronounced and result in anxiety or anger.

<span class="mw-page-title-main">Mood stabilizer</span> Psychiatric medication used to treat mood disorders

A mood stabilizer is a psychiatric medication used to treat mood disorders characterized by intense and sustained mood shifts, such as bipolar disorder and the bipolar type of schizoaffective disorder.

<span class="mw-page-title-main">Seasonal affective disorder</span> Medical condition

Seasonal affective disorder (SAD) is a mood disorder subset in which people who typically have normal mental health throughout most of the year exhibit depressive symptoms at the same time each year. It is commonly, but not always, associated with the reductions or increases in total daily sunlight hours that occur during the summer or winter.

<span class="mw-page-title-main">Light therapy</span> Therapy involving intentional exposure to sunlight

Light therapy, also called phototherapy or bright light therapy is the exposure to direct sunlight or artificial light at controlled wavelengths in order to treat a variety of medical disorders, including seasonal affective disorder (SAD), circadian rhythm sleep-wake disorders, cancers, and skin wound infections. Treating skin conditions such as neurodermatitis, psoriasis, acne vulgaris, and eczema with ultraviolet light is called ultraviolet light therapy.

Non-24-hour sleep–wake disorder is one of several chronic circadian rhythm sleep disorders (CRSDs). It is defined as a "chronic steady pattern comprising [...] daily delays in sleep onset and wake times in an individual living in a society". Symptoms result when the non-entrained (free-running) endogenous circadian rhythm drifts out of alignment with the light–dark cycle in nature. Although this sleep disorder is more common in blind people, affecting up to 70% of the totally blind, it can also affect sighted people. Non-24 may also be comorbid with bipolar disorder, depression, and traumatic brain injury. The American Academy of Sleep Medicine (AASM) has provided CRSD guidelines since 2007 with the latest update released in 2015.

<span class="mw-page-title-main">Mixed affective state</span> Medical condition

A mixed affective state, formerly known as a mixed-manic or mixed episode, has been defined as a state wherein features and symptoms unique to both depression and (hypo)mania, including episodes of anguish, despair, self doubt, rage, excessive impulsivity and suicidal ideation, sensory overload, racing thoughts, heightened irritability, decreased "need" for sleep and other symptoms of depressive and manic states occur either simultaneously or in very short succession.

Interpersonal and social rhythm therapy (IPSRT) is an intervention for people with bipolar disorder (BD). Its primary focus is stabilizing the circadian rhythm disruptions that are common among people with bipolar disorder (BD). IPSRT draws upon principles from interpersonal psychotherapy, an evidence-based treatment for depression and emphasizes the importance of daily routine (rhythm).

The emphasis of the treatment of bipolar disorder is on effective management of the long-term course of the illness, which can involve treatment of emergent symptoms. Treatment methods include pharmacological and psychological techniques.

In medicine, a prodrome is an early sign or symptom that often indicates the onset of a disease before more diagnostically specific signs and symptoms develop. It is derived from the Greek word prodromos, meaning "running before". Prodromes may be non-specific symptoms or, in a few instances, may clearly indicate a particular disease, such as the prodromal migraine aura.

Bipolar II disorder (BP-II) is a mood disorder on the bipolar spectrum, characterized by at least one episode of hypomania and at least one episode of major depression. Diagnosis for BP-II requires that the individual must never have experienced a full manic episode. Otherwise, one manic episode meets the criteria for bipolar I disorder (BP-I).

The associated features of bipolar disorder are clinical phenomena that often accompany bipolar disorder (BD) but are not part of the diagnostic criteria for the disorder. There are several childhood precursors in children who later receive a diagnosis of bipolar disorder. They may show subtle early traits such as mood abnormalities, full major depressive episodes, and attention-deficit hyperactivity disorder. BD is also accompanied by changes in cognition processes and abilities. This includes reduced attentional and executive capabilities and impaired memory. How the individual processes the world also depends on the phase of the disorder, with differential characteristics between the manic, hypomanic and depressive states. Some studies have found a significant association between bipolar disorder and creativity.

Chronotherapy, also called chronotherapeutics or chronotherapeutic drug delivery, refers to the coordination of therapeutic treatments with an individual's circadian or other rhythmic cycles. This may be done to maximize effectiveness of a specific treatment, minimize possible side effects, or both.

<span class="mw-page-title-main">Lithium (medication)</span> Type of psychiatric medication

Certain lithium compounds, also known as lithium salts, are used as psychiatric medications, primarily for bipolar disorder and for major depressive disorder. In lower doses, other salts such as lithium citrate are known as nutritional lithium and have occasionally been used to treat ADHD. Lithium is taken orally.

The General Behavior Inventory (GBI) is a 73-question psychological self-report assessment tool designed by Richard Depue and colleagues to identify the presence and severity of manic and depressive moods in adults, as well as to assess for cyclothymia. It is one of the most widely used psychometric tests for measuring the severity of bipolar disorder and the fluctuation of symptoms over time. The GBI is intended to be administered for adult populations; however, it has been adapted into versions that allow for juvenile populations, as well as a short version that allows for it to be used as a screening test.

<span class="mw-page-title-main">Endoxifen</span> Chemical compound

Endoxifen, also known as 4-hydroxy-N-desmethyltamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group as well as a protein kinase C (PKC) inhibitor. It is under development for the treatment of estrogen receptor-positive breast cancer and for the treatment of mania in bipolar disorder. It is taken by mouth.

<span class="mw-page-title-main">Biology of bipolar disorder</span> Biological Study Of Bipolar Disorder

Bipolar disorder is an affective disorder characterized by periods of elevated and depressed mood. The cause and mechanism of bipolar disorder is not yet known, and the study of its biological origins is ongoing. Although no single gene causes the disorder, a number of genes are linked to increase risk of the disorder, and various gene environment interactions may play a role in predisposing individuals to developing bipolar disorder. Neuroimaging and postmortem studies have found abnormalities in a variety of brain regions, and most commonly implicated regions include the ventral prefrontal cortex and amygdala. Dysfunction in emotional circuits located in these regions have been hypothesized as a mechanism for bipolar disorder. A number of lines of evidence suggests abnormalities in neurotransmission, intracellular signalling, and cellular functioning as possibly playing a role in bipolar disorder.

Sleep is known to play an important role in the etiology and maintenance of bipolar disorder. Patients with bipolar disorder often have a less stable and more variable circadian activity. Circadian activity disruption can be apparent even if the person concerned is not currently ill.

<span class="mw-page-title-main">Melatonin as a medication and supplement</span> Supplement and medication used to treat sleep disorders

Melatonin is a dietary supplement and medication as well as naturally occurring hormone. As a hormone, melatonin is released by the pineal gland and is involved in sleep–wake cycles. As a supplement, it is often used for the attempted short-term treatment of disrupted sleep patterns, such as from jet lag or shift work, and is typically taken orally. Evidence of its benefit for this use, however, is not strong. A 2017 review found that sleep onset occurred six minutes faster with use, but found no change in total time asleep.

References

  1. Phelps, James (2008-01-01). "Dark therapy for bipolar disorder using amber lenses for blue light blockade". Medical Hypotheses. 70 (2): 224–229. doi:10.1016/j.mehy.2007.05.026. ISSN   0306-9877. PMID   17637502.
  2. Childs, Morgan (2018-07-06). "A Week of Darkness, for Your Health". The Atlantic. Retrieved 2019-11-23.
  3. "Dark Therapy". PsychEducation. 17 September 2014. Retrieved 2019-04-28.
  4. Phelps J (2016). "A powerful non-pharmacologic treatment for mania - virtually". Bipolar Disord (Commentary). 18 (4): 379–82. doi:10.1111/bdi.12393. PMID   27218661.
  5. Barbini, Barbara; Benedetti, Francesco; Colombo, Cristina; Dotoli, Danilo; Bernasconi, Alessandro; Cigala‐Fulgosi, Mara; Florita, Marcello; Smeraldi, Enrico (2005). "Dark therapy for mania: a pilot study". Bipolar Disorders. 7 (1): 98–101. doi:10.1111/j.1399-5618.2004.00166.x. ISSN   1399-5618. PMID   15654938.
  6. Phelps, James (2008-01-01). "Dark therapy for bipolar disorder using amber lenses for blue light blockade". Medical Hypotheses. 70 (2): 224–229. doi:10.1016/j.mehy.2007.05.026. ISSN   0306-9877. PMID   17637502.
  7. Henriksen, Tone; Skrede, Silje; Ole, Fasmer; Schoeyen, Helle; Leskauskaite, Ieva; Bjørke‐Bertheussen, Jeanette; Assmus, Jörg; Hamre, Børge; Grønli, Janne; Lund, Anders (26 May 2016). "Blue‐blocking glasses as additive treatment for mania: a randomized placebo‐controlled trial". Bipolar Disorders. 18 (3): 221–232. doi:10.1111/bdi.12390. PMC   5089565 . PMID   27226262.
  8. Barbini, B (2005). "Dark Therapy for Mania: a pilot study". Bipolar Disorders. 7 (1): 98–101. doi:10.1111/j.1399-5618.2004.00166.x. PMID   15654938.
  9. Henriksen, Tone; Skrede, Silje; Ole, Fasmer; Schoeyen, Helle; Leskauskaite, Ieva; Bjørke‐Bertheussen, Jeanette; Assmus, Jörg; Hamre, Børge; Grønli, Janne; Lund, Anders (26 May 2016). "Blue‐blocking glasses as additive treatment for mania: a randomized placebo‐controlled trial". Bipolar Disorders. 18 (3): 221–232. doi:10.1111/bdi.12390. PMC   5089565 . PMID   27226262.
  10. Franke, L.; Sülflow, D.; Stark, K.; Piazena, H.; Uebelhack, R. (2009-01-01). "P03-246 Acute effect of blue light exposition on well-being and melatonin secretion in humans". European Psychiatry. 17th EPA Congress - Lisbon, Portugal, January 2009, Abstract book. 24: S1245. doi: 10.1016/S0924-9338(09)71478-6 . ISSN   0924-9338. S2CID   144027952.